Gubra A/S/€GUBRA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Gubra A/S
Gubra A/S is a biotechnology company focused on the research and development of peptide-based therapeutics and innovative technologies for the treatment of obesity, diabetes, and related metabolic disorders. The company's core business includes providing preclinical contract research services with an emphasis on metabolic and fibrotic diseases. Gubra is headquartered in Hørsholm, Denmark. The company emphasizes its expertise in translational models and histology, supporting its unique strategic positioning in the biotech contract research space. By integrating computational biology with experimental data, Gubra aims to deliver comprehensive insights that aid in drug discovery and development.
Ticker
€GUBRA
Sector
Primary listing
XGAT
Employees
275
Headquarters
Horsholm, Denmark
Website
Gubra A/S Metrics
BasicAdvanced
€873M
3.69
€14.50
0.68
€8.20
15.33%
Price and volume
Market cap
€873M
Beta
0.68
52-week high
€100.29
52-week low
€42.00
Average daily volume
8K
Dividend rate
€8.20
Financial strength
Current ratio
1.72
Quick ratio
1.716
Long term debt to equity
6.401
Total debt to equity
7.628
Interest coverage (TTM)
17.02%
Profitability
EBITDA (TTM)
295.377
Gross margin (TTM)
96.36%
Net profit margin (TTM)
66.22%
Operating margin (TTM)
83.47%
Effective tax rate (TTM)
20.62%
Revenue per employee (TTM)
€1,284,860
Management effectiveness
Return on assets (TTM)
78.15%
Return on equity (TTM)
208.03%
Valuation
Price to earnings (TTM)
3.689
Price to revenue (TTM)
2.432
Price to book
5.36
Price to tangible book (TTM)
5.43
Price to free cash flow (TTM)
2.816
Free cash flow yield (TTM)
35.51%
Free cash flow per share (TTM)
18.999
Dividend yield (TTM)
15.33%
Growth
Revenue change (TTM)
1,078.32%
Earnings per share change (TTM)
-3,958.72%
Bulls say / Bears say
Gubra’s exclusive license agreement with AbbVie for GUBamy is valued up to $2.2 billion—including a $350 million upfront payment and $1.875 billion in milestone payments—providing Gubra with substantial non-dilutive capital and validating its peptide innovation (Business Standard)
Initial Phase 1 results for GUBamy showed a dose-dependent mean body-weight reduction of around 3 percent over six weeks, compared to a 1 percent weight gain on placebo, highlighting early efficacy and favorable tolerability (Business Standard)
Gubra’s shares surged 29 percent at the open following news of the AbbVie licensing deal—its biggest one-day gain since 2024—and the stock has more than tripled over the past year on optimism for its obesity pipeline (Reuters)
Gubra’s CRO business outlook was downgraded after H1 2025 revenue declined 2 percent year-on-year, and the company now expects full-year CRO revenue to be slightly below 2024 levels versus the previous forecast of 10–20 percent growth, highlighting longer decision cycles in the U.S. market (Reuters)
Gubra is facing growing competition in the obesity market from established GLP-1 leaders and new RNA-based therapies, as demonstrated by Novo Nordisk’s recent partnership with Replicate BioScience and Eli Lilly’s collaborations, which could limit GUBamy’s market opportunity (Reuters)
The $350 million upfront payment and future milestone payments from AbbVie’s license deal for GUBamy are contingent upon successful regulatory and clinical development milestones, meaning Gubra remains exposed to the typical failure risks seen in biotech R&D (AbbVie)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gubra A/S stock?
Gubra A/S (GUBRA) has a market cap of €873M as of September 02, 2025.
What is the P/E ratio for Gubra A/S stock?
The price to earnings (P/E) ratio for Gubra A/S (GUBRA) stock is 3.69 as of September 02, 2025.
Does Gubra A/S stock pay dividends?
Yes, the Gubra A/S (GUBRA) stock pays dividends to shareholders. As of September 02, 2025, the dividend rate is €8.20323 and the yield is 15.33%. Gubra A/S has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Gubra A/S dividend payment date?
The next Gubra A/S (GUBRA) dividend payment date is unconfirmed.
What is the beta indicator for Gubra A/S?
Gubra A/S (GUBRA) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.